Cebpg, also known as CCAAT enhancer binding protein gamma, is a gene implicated in myeloid differentiation and plays critical roles in various physiological and pathological processes. It has been associated with multiple signaling pathways, such as the PI3K-AKT signaling pathway, and is involved in processes like cell proliferation, migration, and apoptosis [2,3]. Genetic models, including gene knockout (KO) or conditional knockout (CKO) mouse models, can be valuable for studying its functions.

In ovarian cancer, knockdown of Cebpg inhibited cancer progression, and it was identified as a regulator of ferroptosis, suppressing it through transcriptional control of SLC7A11 [1]. In acute myeloid leukemia (AML), shRNA-mediated down-regulation of Cebpg showed that it promotes AML cell proliferation by activating EIF4EBP1 [2]. In esophageal squamous cell carcinoma, Cebpg significantly promotes cell proliferation and migration both in vitro and in vivo by activating the PI3K-AKT signaling pathway [3].

In conclusion, Cebpg is a crucial regulator in multiple disease conditions. Studies using KO or CKO mouse models, as well as in vitro knockdown experiments, have revealed its role in promoting the progression of cancers like ovarian, AML, and esophageal squamous cell carcinoma. These findings suggest Cebpg could be a potential therapeutic target in these disease areas.

References:

1. Zhang, Xiaoqian, Zheng, Xiaocui, Ying, Xiang, Yin, Yujia, Wang, Xipeng. 2023. CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer. In Journal of translational medicine, 21, 334. doi:10.1186/s12967-023-04136-0. https://pubmed.ncbi.nlm.nih.gov/37210575/

2. Jiang, You, Wu, Shui-Yan, Chen, Yan-Ling, Fang, Fang, Lu, Jun. 2021. CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1. In Cancer cell international, 21, 598. doi:10.1186/s12935-021-02305-z. https://pubmed.ncbi.nlm.nih.gov/34743716/

3. Huang, Yongsheng, Lin, Lehang, Shen, Zhuojian, Lu, Daning, Yin, Dong. 2020. CEBPG promotes esophageal squamous cell carcinoma progression by enhancing PI3K-AKT signaling. In American journal of cancer research, 10, 3328-3344. doi:. https://pubmed.ncbi.nlm.nih.gov/33163273/